
#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 12 months ago Tagged analysis antitrust biologics biosimilars competition economics generics intellectual property law litigation market payment pharmaceutical settlement
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 2 years ago Tagged biosimilars comfort letter COVID denigration divisional patents European Commission generics patent linkage pharmaceuticals
Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]